[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-drug-resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-drug-resistance":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100604208",false,"NCT07146529","Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis","PRINAVIH","Inclusion Criteria:\n\n* Participant (male or female) aged 18 years or older ;\n* Participant newly diagnosed in the laboratory, for whom mandatory HIV seropositivity reporting to Santé Publique France (SPF) is required ;\n* Participant naïve to all antiretroviral treatments (except PrEP and\u002For post-exposure prophylaxis \\[PEP\\]) ;\n* Participant with an available HIV resistance genotype, including amplification of at least reverse transcriptase and protease ;\n* Participant who has not objected to participating in the study.\n\nExclusion Criteria:\n\n* Participant who objects to the use of their data ;\n* Participant currently on antiretroviral treatment ;\n* Participant subject to legal protection measures (safeguard of justice).","ALL","18 Years",{"count":18,"type":19},30060,"ESTIMATED","1 Day","OBSERVATIONAL","The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1",[24,25,26],"HIV Seropositivity","HIV Drug Resistance","HIV Infections",[28,29,30,31,32,33,34],"Genotyping","HIV-1","HIV drug resistance","Transmitted resistance","Viral diversity","Transmission clusters","Primary infection","NOT_YET_RECRUITING","2025-08-21",{"date":38,"type":39},"2025-08-28","ACTUAL",{"date":41,"type":19},"2025-09",{"date":43,"type":19},"2036-09",{"name":45,"class":46},"ANRS, Emerging Infectious Diseases","OTHER_GOV",""]